ACE applications are now open through October 15. Join a national network committed to providing high-quality, comprehensive Ataxia care. Apply Now!
Written by Dr. Judit M. Perez Ortiz Edited by Dr. Sriram Jayabal In a new study, scientists have found that “zapping” the brain with an electromagnetic wand may someday help patients with spinocerebellar ataxia. In an era of ever-evolving technological advances used for personal entertainment and space travel, medical scientists Read More…
Written by Jorge Diogo Da Silva Edited by Dr. David Bushart Normalizing neuronal dysfunction in SCA3/MJD by activating a receptor inside cells Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an inherited neurodegenerative disease that typically begins in mid-adulthood. This disease causes loss of coordination and Read More…
Written by Dr. Marija Cvetanovic Edited by Larissa Nitschke Purkinje cells (a type of neuron in the cerebellum) are the most vulnerable cells in many Spinocerebellar Ataxias (SCAs). While animal models of SCA have been very fruitful in understanding the mechanisms of Purkinje cell neurodegeneration, none of these models have Read More…
Written by Eviatar Fields Edited by Dr. Vitaliy Bondar Scientists use Brain Derived Neurotrophic Factor to delay motor symptom onset and cell death in a mouse model of Spinocerebellar Ataxia Type 1 Spinocerebellar ataxia type 1 (SCA1) is a rare neurodegenerative disease that affects about 2 out of 100,000 individuals. Read More…
Written by Dr. Ambika Tewari Edited by Dr. Sriram Jayabal New research identifies the cell type in the cerebellum that is vital for a specific form of motor learning Locomotion – the process of moving oneself from one place to another – is highly adaptive. Depending on our current needs, Read More…
Written by Dr. Carolyn J. Adamski Edited by Dr. Judit M Perez Ortiz A research group uncovers a drug target to potentially correct motor phenotypes across several cerebellar ataxias. When someone is diagnosed with spinocerebellar ataxia (SCA), their symptoms may look very similar despite the fact that different genes are causing the Read More…
Written by Dr. Colleen A. Stoyas Edited by Dr. Monica Banez Duke University researchers have found that altered cellular metabolism and mitochondrial dysfunction play a central role in spinocerebellar ataxia type 7 (SCA7), a result that has therapeutic implications for this disease. Spinocerebellar ataxia type 7 (SCA7) is a dominantly-inherited ataxia Read More…
Written by Dr. Chandrakanth Edamakanti Edited by Dr. David Bushart VEGF nanoparticles offer a new avenue for developing treatments for SCA1 and other neurodegenerative disorders Spinocerebellar ataxia type 1 (SCA1) is a neurogenerative disorder with symptoms that typically begin in the third or fourth decade of life. The disease is Read More…
Written by Dr. Lauren R. Moore Edited by Larissa Nitschke Creatine, a common dietary supplement taken by athletes, delays symptoms and improves balance and strength in SCA3 mice. Could a common nutritional supplement used by athletes to boost performance also provide benefits to ataxia patients? This was the main question Read More…
Written by Anna Cook Edited by Dr. Monica Banez Researchers successfully use an existing multiple sclerosis drug to improve performance in an SCA6 mouse model Spinocerebellar ataxia type 6 (SCA6) is a rare hereditary movement disorder affecting 5 of every 100,000 people worldwide1. The disease is caused by the expansion Read More…
